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INTRODUCTION
Colon cancer is the third most common tumor world-
wide (1). According to the Turkish Ministry of Health 
2004–2006 Cancer Statistics, the age-standardized inci-
dence rate of colorectal cancer in Turkey is 17.0 in men 
and 11.7 in women per 100,000 people (2,3), while re-
cent epidemiological data indicate that colon cancer is 
more frequent than rectum cancer (4).
Given that most colorectal cancers initially present with 
non-emergency symptoms, such as rectal bleeding, ab-
dominal pain, or a change in bowel habits (5), earlier 
diagnosis has been suggested to arise not only from 
screening but also from the improved recognition of 
symptomatic cancers (6).
Although several factors, such as pathological staging, 
vascular and perineural invasion, residual tumor, serum 
carcinoembryogenic antigen levels, and radial margins, 
were investigated in terms of predicting outcome, limited 
data are available on the association of the clinical presen-
tation with outcome in patients with colon cancer (6-8).
Therefore, the present study was designed to evaluate 
the association of presenting symptoms with staging, 
grading, and postoperative 3-year mortality in patients 
with stage I–III non-metastatic colon cancer.
MATERIALS AND METHODS
Study population
Of 258 patients who were diagnosed with non-meta-
static stage I–III colon cancer and underwent surgical 
operation at a tertiary care hospital between 2005 and 
2010, 132 patients [mean (standard deviation; SD) age: 
63.0 (10.0) years; males: 56.0%, females: 44%] who met 
Address for Correspondence: Şafak Kızıltaş   E-mail: safakkiziltas@hotmail.com
Received:  December 14, 2015 Accepted: February 20, 2016
© Copyright 2016 by The Turkish Society of Gastroenterology • Available online at www.turkjgastroenterol.org • DOI: 10.5152/tjg.2016.15508
BOWEL
239
ABSTRACT
Background/Aims: To evaluate the association of presenting symptoms with staging, grading, and postopera-
tive 3-year mortality in patients with colon cancer.
Materials and Methods: A total of 132 patients—with a mean (standard deviation; SD) age of 63.0 (10.0) years 
and of whom 56.0% were males—with non-metastatic stage I–III colon cancer were included. Symptoms prior 
to diagnosis were evaluated with respect to tumor localization, tumor node metastasis (TNM) stage, histologi-
cal grade, and postoperative 3-year mortality.
Results: Constipation and abdominal pain were the two most common symptoms appearing first (29.5% and 
16.7%, respectively) and remained most predominant (25.0% and 20.0%, respectively) up to diagnosis. The frequen-
cy of admission symptoms significantly differed with respect to tumor location, TNM stage and histological grade. 
The postoperative 3-year survival rate was 61.4%. Multivariate logistic regression revealed that melena and rectal 
bleeding increased the likelihood of 3-year mortality by 13.6-fold (p=0.001) and 4.08-fold (p=0.011), respectively.
Conclusion: Our findings revealed differences in presenting symptom profiles with respect to the time of mani-
festation and predominance as well as to the TNM stage, histological grade, and tumor location. Given that me-
lena and rectal bleeding increased the 3-year mortality risk by 13.6-fold and 4.08-fold, respectively, our findings 
indicate the association of admission symptoms with outcome among patients with colon cancer. 
Keywords: Colon cancer, symptoms, prognosis, mortality
O
ri
gi
na
l A
rt
ic
le
the inclusion criteria were included in this retrospective study. 
Survival data were obtained from the medical records as well 
as from patients and/or relatives. Patients with recto-sigmoid 
cancer, stage IV colon cancer, mortality within the postopera-
tive first month or mortality not related to colon cancer, and 
patients who themselves or relatives could not be reached to 
obtain data on survival at the time of the study (2013) were 
excluded (n=126) from the study.
The study was conducted in full accordance with local Good 
Clinical Practice (GCP) guidelines and current legislation. While 
the present study was exempt from the requirement of informed 
consent in relation to its retrospective design, the permission was 
obtained from Medeniyet University School of Medicine Ethics 
Committee for the use of patient data for publication purposes 
(Date of approval: 08/07/2013, Reference number: 2013/0012).
Study parameters
Data on patient demographics, family history of malignancy, tu-
mor characteristics [localization, histological type, tumor node 
metastasis (TNM) stage, histological grade, perineural and peri-
vascular invasion], symptoms at admission (the first symptom 
appearing, the most predominant symptoms and symptoms 
experienced at least once up to diagnosis), symptom duration 
(days from symptom occurrence to the diagnosis), and survival 
were obtained from the medical records, while the data on the 
latest status of the patients in terms of survival were obtained 
via contacting the patients themselves or their close relatives. 
Symptoms prior to diagnosis were evaluated with respect to 
tumor localization, TNM stage, and histological grade.
Because the last patient included in the study had a follow-
up of 3 years, the patients were classified into two groups as 
survived ≤ and >3 years after the operation and were included 
in univariate and multivariate logistic regression analyses to de-
termine the impact of pre-operative symptoms on postopera-
tive 3-year mortality. The association of gender, age, and family 
history of malignancy with survival was also evaluated.
Statistical analysis
Statistical analysis was made using IBM SPSS Statistics (IBM 
Corp. Released 2012, IBM SPSS Statistics for Windows, Version 
21.0.; Armonk, NY, USA). In addition to descriptive statistics, the 
Chi-square test for the comparison of categorical data, and 
univariate and mutually adjusted logistic regression models 
for elucidating the impact of clinical symptoms on 3-year mor-
tality after surgical treatment were used. Data were expressed 
as the mean (SD), minimum-maximum, percent (%), and 95% 
confidence interval (CI) where appropriate. p<0.05 was consid-
ered statistically significant.
RESULTS
Patient demographics and baseline clinical characteristics
Over a period of 8 years, 132 patients met the inclusion criteria 
for the study. Overall, 56.0% of our patients were males, and 
the median age of all the patients was 63 years; 40.2% of pa-
tients were aged 60-69 years (Table 1). The tumors were mostly 
located at the descending (38.6%) or ascending (34.1%) colon, 
and 69.7% of tumors were adenocarcinomas; the other base-
line clinical characteristics related to the cancer are presented 
in Table 1.
Symptoms preceding diagnosis
Constipation and abdominal pain were the two most common 
symptoms that appeared first (29.5% and 16.7%, respectively) 
and remained as the most predominant (25.0% and 20.0%, 
respectively) of the overall symptoms experienced up to di-
agnosis (Table 2). While not commonly reported among the 
first symptoms to appear, melena and rectal bleeding become 
the predominant symptom experienced by 14.4% and 12.9% 
of patients, respectively (Table 2). A change in bowel habits 
(72.7%), loss of appetite (47.0%), and weight loss (46.2%) were 
the most common symptoms experienced at least once up to 
diagnosis (Table 2). Half of the patients (49.2%) had received a 
diagnosis within 90 days of symptom onset (Table 2).
Symptoms with respect to tumor location, TNM stage, and 
histological grade
The frequency of admission symptoms, other than nausea, 
change in bowel habits, and loss of appetite were significantly 
different in the subgroups of patients according to tumor loca-
tion (Table 3). In summary, the rate of abdominal pain (55.6%, 
p=0.001), rectal bleeding (55.6%, p=0.001), and weight loss 
(66.7%, p=0.003) were much higher among transverse colon 
tumors, while constipation (62.7%, p=0.001) was more fre-
quent among patients with descending colon cancer; melena 
was noted more frequently in patients with ascending rather 
than transverse colon tumors (35.6% vs. 11.1%, p=0.001), while 
it was seen in none of the descending colon tumor patients 
(Table 3).
When Stage II vs. Stage III tumors were compared, diarrhea 
(0.0% vs. 100.0%, p=0.002), melena (0.5% vs. 95.0%, p=0.004), 
rectal bleeding (11.0% vs. 89.0%, p=0.002), change in bowel 
habits (21.0% vs. 79.0%, p=0.0001), and loss of appetite (19.0% 
vs. 81.0%, p=0.004) were the admission symptoms with sig-
nificantly higher percentages among patients at a higher TNM 
stage, while the rate of vomiting (p=0.01), melena (p=0.02), 
change in bowel habits (p=0.01), weight loss (p=0.004), and 
loss of appetite (p=0.002) significantly increased with histologi-
cal grade (Table 3).
Postoperative three-year survival
Postoperative survival time was less than 1 year in 26 (19.6) 
and 1–3 years in 25 (18.9) patients, with a 3-year survival rate 
of 61.4%. No significant difference in terms of mean (SD) age 
[63.0 (11.0) vs. 62.0 (10.0) years, p=0.51] and family history of 
malignancy [11 patients (50.0%) for each, p=0.23] was noted 
between patients who had died in less than 3 years or survived 
>3 years, postoperatively.
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Symptoms with respect to three-year mortality
Upon univariate analysis, all admission symptoms other than 
constipation were significantly less frequent among the >3-
year survivors. Upon univariate logistic regression, abdominal 
pain (p=0.012), diarrhea (p=0.011), melena (p<0.001), rectal 
bleeding (p=0.005), weight loss (p<0.001), and loss of appetite 
   Mean (SD) 
   median (min-max)
   63.0 (10.0)
Age (year)  63.0 (40.0-87.0)
Age groups (years)    n (%)
 40-49  17 (12.9)
 50-59  34 (25.8)
 60-69  53 (40.2)
 70-80  23 (17.4)
 ≥80  5 (3.8)
Gender, Female/Male  58 (44.0)/74 (56.0)
Family history for malignancy  22 (16.7)
Tumor localization    
 Descending colon  51 (38.6)
 Ascending colon  45 (34.1)
 Transverse colon  36 (27.3)
Histological type 
 Adenocarcinoma  92 (69.7)
 Non-adenocarcinoma   17 (12.9)
    Signet ring cell carcinoma  8 (6.1)
     Mucinous carcinoma  6 (4.6)
    Mixed type  3 (2.3)
Histological grade 
 GI- well differentiated  9 (6.8)
 GII- moderately differentiated  58 (43.9)
 GIII- poorly differentiated  20 (4.8)
 Missing data  19
TN stagea 
 Tumoral invasion  
     T1   2 (1.7)
     T2  36 (31.2)
     T3  77 (66.9)  
 Missing data  17
 Lymph node positivityb 
     N0  35 (33.7)
     N1  38 (36.5)
     N2   25 (24.0)
     N3   6 (5.8)
 Missing data  28
Neurovascular invasion 
 Perivascular invasion  18 (16.5)
 Perineural invasion   17 (15.6)
 Missing data  23
TN: tumor node 
aPatients were evaluated based on tumoral invasion and lymph node positivity, since patients 
with metastatic tumors were not included in the study
bN1: 1-3 pericolic node positive; N2: ≥4 pericolic node positive; N3: arterial node positive
Table 1. Patient demographics and baseline clinical characteristics (n=132)
Symptom first appeared n (%)
Constipation  39 (29.5)
Abdominal pain 22 (16.7)
Change in bowel habits  16 (12.1)
Loss of appetite 15 (11.4)  
Nausea/vomiting 14 (10.6)
Melena  8 (6.1)
Rectal bleeding 7 (5.3)
Weight loss 1 (0.8 )
Most predominant symptomb  
Constipation  33 (25.0)
Abdominal pain 27 (20.5)
Melena 19 (14.4)
Rectal bleeding 17 (12.9)
Change in bowel habits  11 (8.3)
Loss of appetite 5 (3.8)
Nausea/vomiting 5 (3.8)
Weight loss 4 (3.0)
Symptom experienced at least onceb  
Change in bowel habits 96 (72.7)
Loss of appetite 62 (47.0)
Weight loss 61 (46.2)
Constipation 49 (37.1)
Abdominal pain 47 (35.6)
Nausea 41 (31.1)
Rectal bleeding 36 (27.3)
Vomiting  27 (20.5)
Diarrhea  22 (16.7)
Melena 20 (15.2)
Days from (any) symptom occurrence to diagnosis 
1-30 days  39 (29.5)
31-90 days  26 (19.7)
91-180 days  18 (13.6)
181-365 days  27 (20.5)
1-3 years  15 (11.4)
≥3years  7 (5.3)
aat least 3 kg unintentional weight loss not related to other causes 
bfrom occurrence to diagnosis
Table 2. Symptoms preceding the diagnosis (n=132)
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(p<0.001) were found to be risk factors of death in 3 years. On 
the other hand, after adjusting by mutually adjusted multivari-
ate logistic regression, only having melena and rectal bleeding 
on admission were confirmed to be independent predictors of 
3-year mortality, which increased the likelihood of mortality in 
the postoperative 3 years by 13.6-fold (p=0.001) and 4.08-fold 
(p=0.011), respectively (Table 4).
DISCUSSION
Our findings in a cohort of patients with non-metastatic stage 
I–III colon cancer revealed that constipation and abdominal 
pain were the most common symptoms that appeared first, 
while a change in bowel habits was experienced by the major-
ity of patients at least once up to diagnosis; while melena and 
rectal bleeding were the later symptoms that increased the 
likelihood of mortality in the postoperative 3 years by 13.6-fold 
(p=0.001) and 4.08-fold (p=0.011), respectively.
Our findings are consistent with the general profile of patients 
with colon cancer described in the first prospective long-term 
registry study (A Turkish Oncology Group trial) on the epidemi-
ology of colorectal cancer in Turkey, which revealed male pre-
dominance (60.7%), a mean age of 59.63 years, a median 3.0 
months duration between the first symptoms and diagnosis, 
and the involvement of ascending colon, descending colon, 
and transverse colon in 9.7%, 8.1%, and 7.1% of patients with 
colon cancer (4).
While findings in our cohort were also similar to other cohorts 
of patients with colon cancer in the past studies in terms of 
          Tumor localization    Tumor TNM stagea            Histological grade
Symptoms, n (%) Ascending colon Descending colon Transverse colon p* Stage II Stage III p* Grade I Grade II Grade GIII p*
Abdominal pain 6 (13.6) 21 (42.0) 20 (55.6) 0.001 14 (36) 25 (64.0) 0.51 3 (8.0) 23 (59.0) 13 (33.0) 0.47
Diarrhea 14 (31.0) 0 (0.0) 8 (22.0) 0.001 0 (0.0) 18 (100.0) 0.002 0 (0.0) 8 (44.0) 10 (56.0) 0.21
Constipation 5 (11.1) 32 (62.7) 12 (33.3) 0.001 13 (35.0) 24 (65.0) 0.61 2 (5.0) 15 (41.0) 20 (54.0) 0.13
Nausea 13 (28.9) 16 (31.4) 12 (33.3) 0.91 11 (30.0) 26 (70.0) 0.74 0 (0.0) 20 (54.0) 17 (46.0) 0.09
Vomiting 14 (33.3) 5 (9.8) 8 (22.2) 0.02 5 (22.0) 18 (78.0) 0.21 5 (22.0) 8 (35.0) 10 (43.0) 0.02
Melena 16 (35.6) 0 (0.0) 4 (11.1) 0.001 1 (5.0) 19 (95.0) 0.004 0 (0.0) 6 (30.0) 14 (70.0) 0.01
Rectal bleeding 1 (2.2) 15 (29.4) 20 (55.6) 0.001 4 (11.0) 31 (89.0) 0.002 1 (3.0) 23 (66.0) 11 (31.0) 0.09
Change in bowel habits 29 (61.4) 41 (80.4) 26 (72.2) 0.21 18 (21.0) 66 (79.0) 0.0001 3 (4.0) 44 (52.0) 37 (44.0) 0.01
Weight loss 13 (28.9) 24 (47.1) 24 (66.7) 0.003 14 (25.0) 42 (75.0) 0.12 2 (4.0) 23 (41.0) 31 (55.0) 0.004
Loss of appetite 17 (37.8) 26 (51.0) 19 (52.8) 0.31 11 (19.0) 46 (81.0) 0.004 2 (4.0) 23 (40.0) 32 (56.0) 0.002
TNM: tumor node metastasis; Grade I: well differentiated; Grade II: moderately differentiated; Grade III: poorly differentiated
aAlthough 2 patients had T1 stage tumors, lymph node evaluation revealed TNM stage III category in these patients and thus none of the patients was in TNM stage I category.
*Chi-square test
Table 3. Symptoms with respect to tumor location, TNM stage and histological grade
 Survivors for  Decedents 
 >3 yrs (n=81) (n=51)  Univariate analysisa   Multivariate analysisb
Symptoms at admission n (%) n (%) OR 95% CI (LB; UB) p OR 95% CI  p
Abdominal pain 22 (27.2) 25 (49.0) 2.58 1.24; 5.38 0.012 1.13 0.34; 3.73 0.841
Diarrhea 8 (9.9) 14 (27.5) 3.45 1.33; 8.97 0.011 1.66 0.50; 5.47 0.405
Constipation 32 (39.5) 17 (33.3) 0.77 0.37; 1.59 0.485  Not included
Nausea-vomiting 18 (22.2) 23 (45.1) 2.07 0.995; 4.32 0.051* 1.30 0.45; 3.71 0.627
Melena 4 (4.9) 16 (31.4) 8.80 2.74; 28.25 <0.001 13.60 3.00; 61.66 0.001
Rectal bleeding 15 (18.5) 21 (41.2) 3.08 1.40; 6.79 0.005 4.08 1.38; 12.05 0.011
Change in bowel habits 56 (69.1) 40 (78.4) 1.62 0.72; 3.67 0.248  Not included
Weight loss 25 (30.9) 36 (70.6) 5.38 2.50; 11.55 <0.001 1.70 0.35; 8.31 0.510
Loss of appetite 24 (29.6) 38 (74.5) 6.94 3.15; 15.30 <0.001 4.47 0.98; 20.35 0.053
CI: confidence interval; LB: lower bound; UB: upper bound; OR: odds ratio by logistic regression analysis
*included in the multivariate analysis since the univariate p value was marginal
Table 4. Univariate and multivariate regression analyses for symptoms predicting 3-year mortality
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demographics and tumor location, the symptom profile seems 
to differ with respect to quality as well as frequency, with a 
lesser incidence of abdominal pain and rectal bleeding among 
symptoms noted until diagnosis or that had occurred first, re-
spectively (1,6,7,9).
In terms of the admission symptoms, abdominal pain (one 
of the earliest symptoms) and rectal bleeding (a later symp-
tom predicting mortality) were more common in transverse 
colon tumors, while melena, the most significant predictor 
of 3-year postoperative mortality, was the only admission 
symptom that was more common in patients with ascend-
ing colon tumors.
Hence our findings emphasize a close association of the qual-
ity of admission symptoms with progression of the disease and 
a potential role for fecal occult blood test screening in earlier 
detection of the disease prior to manifestation of overt rectal 
bleeding (6) in transverse colon tumors.
In our cohort, diarrhea, melena, rectal bleeding, a change in 
bowel habits, and loss of appetite were the more commonly 
encountered admission symptoms in higher TNM stages. Sig-
nificant differences in the manifestation of symptoms with re-
spect to TNM staging have also been reported in other studies, 
with an increased incidence of abdominal pain, weight loss, 
and a change in bowel habits shown in advanced TNM stages, 
which correlate with more aggressive tumor characteristics 
and an adverse clinical outcome (7,8,10-13).
Melena (more common in ascending colon tumors) and rectal 
bleeding (more common in transverse colon tumors) were the 
only admission symptoms in our cohort that were shown to in-
crease the postoperative 3-year mortality risk, by 13.6-fold and 
4.08-fold, respectively. This seems consistent with the higher 
prevalence of these symptoms at later TNM stages. Likewise, 
a worse prognosis in terms of overall survival in patients with 
right-sided than left-sided colon cancers was also reported in 
a recent meta-analysis (14). Also, tumor location was shown 
to be an independent prognostic factor of 5-year recurrence-
free survival and 5-year overall survival in Stage III colon cancer, 
with a gradual decrease in survival from cecum to sigmoid co-
lon cancer (15).
While, all admission symptoms other than constipation were 
significantly less frequent among the >3-year than <3-year sur-
vivors in the univariate analysis; only abdominal pain, diarrhea, 
melena, rectal bleeding, weight loss, and loss of appetite were 
associated with a higher risk for postoperative 3-year mortality 
in the univariate logistic regression in the present study. More-
over, after mutual adjustment in the multivariate logistic re-
gression, only having melena and rectal bleeding on admission 
were confirmed to be independent predictors that increased 
the likelihood of postoperative 3-year mortality by 13.6-fold 
(p=0.001) and 4.08-fold (p=0.011), respectively.
Our findings indicate the association of admission symptoms 
with mortality from colon cancer. The difference in mortality 
from colorectal cancer with respect to the nature of the first 
clinical manifestations was also shown in a past study con-
ducted with 349 patients with primary colorectal cancer, in 
which, unlike our findings, rectal bleeding was indicated to 
be the most common symptom that occurred first or up to 
diagnosis and was associated with lower mortality (6). Given 
that patients with sigmoid-rectal cancers were not included in 
our study population, rectal bleeding was not among the first 
noted symptoms in our cohort.
Data from a cohort study using the Clinical Practice Research 
Database revealed that patients with colorectal cancer who 
presented without rather than with rectal bleeding, a relevant 
alarm symptom, had a higher mortality rate (HR=1.74, 95% 
CI=1.42 to 2.13, p<0.001) (16). Analysis of the data on patients 
with colon cancer from the Icelandic Cancer Registry (1995–
2004) in a population-based study revealed the increased likeli-
hood of a lower tumor grade and lower frequency of vessel in-
vasion among patients presenting with visible blood in stools 
on admission, while blood in stools was also shown to predict 
survival (HR=0.54) (8).
Given the lower survival from diagnosis to death in patients 
with cancer without rather than with any record of relevant 
alarm symptoms in general (16), a higher alertness among 
physicians to the possibility of colorectal cancer in the case of 
rectal bleeding seems to be associated with the better survival 
in these patients (6,17).
Notably, for data from a past study on the correlation between 
symptoms at admission and the outcome among patients 
with colon cancer, a multivariate analysis controlling for age, 
stage, and the duration of complaints showed that melena was 
strongly associated with mortality (p=0.04, OR=7.4), while rec-
tal bleeding was with survival (p=0.004, OR=0.25) (7). However, 
and consistent with our findings and via multivariate analysis 
on the adjusted mortality, rectal bleeding was reported to be 
associated with mortality and no longer with survival (p=0.02, 
OR=2.5) (7). Also, consistent with the symptom profile in our 
cohort, abdominal pain, a change in bowel habits, and weight 
loss were the most common symptoms, while rectal bleeding 
was the 4th most common symptom (7).
Hence, our findings support the association of clinical presen-
tation with outcome among patients with colon cancer, and 
the importance of certain admission symptoms, such as me-
lena and rectal bleeding, in predicting the outcome among 
patients with colon cancer (7).
Half of our patients had received a diagnosis within 90 days 
of symptom onset, while the 3-year survival rate was 61.4%. 
Similarly, past studies in patients with colon cancer revealed a 
mean of 1.8 months duration of complaints prior to diagnosis 
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and an overall mortality of 39.4% within a median of 36 months 
to follow-up (7) as well as 90 days from symptom onset to diag-
nosis in nearly half of patients and an overall mortality of 59% 
within a median of 421 days of diagnosis (6).
Neither constipation nor abdominal pain was among the sig-
nificant predictors of mortality risk in our cohort, despite the 
fact that they were the two most common symptoms that ap-
peared first and remained predominant up to diagnosis. This 
seems consistent with the published data on the lack of s rela-
tionship between the duration of symptoms and mortality in 
patients with colorectal cancer, even when corrected for pos-
sible confounders (6,16,18-22).
Although the duration of symptoms was not associated with 
the outcome and no relationship has been suggested between 
diagnostic delay and colorectal cancer survival (22), both rectal 
bleeding (significant predictor of mortality risk) and abdominal 
pain (one of the earliest symptoms) were more common in our 
patients with transverse colon tumors. Thus, our findings sup-
port the finding that the symptomatic phase in colon cancers 
might have sufficient duration to offer the possibility of earlier 
diagnosis, leading to mortality benefits (6).
Certain limitations to this study should be considered. First, due 
to the small sample size and retrospective single-center design 
of the present hospital-based study, establishing a temporality 
between cause and effect as well as generalizing our findings 
to the overall patient population with colon cancer would be 
difficult. Second, due to the inadequacy of the available reg-
istration system, a number of patients or their relatives could 
not be reached to obtain data on survival and thus could not 
be included in the final analysis. This appears to be a definite, 
albeit inevitable, weakness of the study. Third, the accuracy of 
data on admission symptoms seems questionable given the 
possible neglect of symptom reporting either by the patients 
or physicians as well as the likelihood of the inability of some 
patients to specify the exact time of symptom onset prior to 
diagnosis. Nevertheless, despite these certain limitations, given 
the paucity of the information available in this area, our find-
ings represent a valuable contribution to the literature.
In conclusion, the present analysis of a retrospective cohort 
of patients with non-metastatic stage I–III colon cancer over 
a period of 8 years revealed a difference in presenting symp-
tom profiles with respect to the time of manifestation and pre-
dominance as well as in terms of TNM stage, histological grade, 
and tumor location. Given that melena and rectal bleeding 
increased the 3-year mortality risk by 13.6-fold and 4.08-fold, 
respectively, our findings indicate the association of admission 
symptoms with outcome among patients with colon cancer. 
Further large-scale, population-based studies are needed to 
provide conclusive evidence on this topic, which, although 
promising, is still scarce.
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